日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reperfusion Pulmonary Hemorrhage Following Mechanical Thrombectomy for Sub-massive Pulmonary Embolism

亚大块肺栓塞机械取栓术后再灌注性肺出血

Bajouka, John; Touza, Ghaid; Patel, Keyur; Affas, Ziad; Lynch, Stephen

Underrepresentation of Women in COPD Pharmacologic Trials Relative to Disease Burden: A Systematic Review and Meta-Analysis

慢性阻塞性肺疾病药物试验中女性患者比例低于疾病负担:系统评价和荟萃分析

Umer, Muhammed; Jagra, Amritpal Singh; Al Seidi, Jumana; Ahmad, Amaar; Touza, Masara; Emehinola, Oluwatosin; Surani, Salim; Hanif, Fizzah Mohammad

Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy.

可定制的病毒样颗粒递送 CRISPR-Cas9 核糖核蛋白,用于有效的眼部新生血管和亨廷顿病基因治疗

Ling Sikai, Zhang Xue, Dai Yao, Jiang Zhuofan, Zhou Xujiao, Lu Sicong, Qian Xiaoqing, Liu Jianping, Selfjord Niklas, Satir Tugce Munise, Lundin Anders, Touza Julia Liz, Firth Mike, Van Zuydam Natalie, Bilican Bilada, Akcakaya Pinar, Hong Jiaxu, Cai Yujia

False negative rate and concordance of ThyGeNEXT®+ThyraMIR® testing with post-thyroidectomy histopathology

ThyGeNEXT®+ThyraMIR® 检测的假阴性率及与甲状腺切除术后组织病理学的一致性

Mohammed, Sobrina S; Mettman, Daniel; Garcia-Touza, Mariana; Ridella, Maricel; Drees, Betty

Corrigendum to "False negative rate and concordance of ThyGeNEXT®+ThyraMIR® testing with post-thyroidectomy histopathology" [J. Clin. Translat. Endocrinol. 40 (2025) 100396]

对“ThyGeNEXT®+ThyraMIR® 检测的假阴性率和与甲状腺切除术后组织病理学的一致性”的更正 [J. Clin. Translat. Endocrinol. 40 (2025) 100396]

Mohammed, Sobrina S; Mettman, Daniel; Garcia-Touza, Mariana; Drees, Betty; Ridella, Maricel

Cognitive, Functional, and Emotional Recovery in Patients with Stroke: A Multidimensional Prospective Analysis

中风患者的认知、功能和情绪恢复:一项多维度前瞻性分析

Pego Pérez, Emilio Rubén; Bermello López, Lourdes; Gómez Fernández, Eva; Marín Arnés, María Del Rosario; Fernández Vázquez, Mercedes; Touza González, Carlota; Núñez Hernández, María Irene

Review of Genomic Drivers of Thyroid Cancer and Their Clinical Implications

甲状腺癌基因组驱动因素及其临床意义综述

Mohammed, Sobrina; Mettman, Daniel; Breier, Axel Hugo; Patel, Vaishali; Garcia-Touza, Mariana

A Stable Switch From Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) to Dolutegravir/Lamivudine (DTG/3TC) in the Absence of Historical Resistance Records: Results From the Switch to Dovato in Patients Suppressed on Biktarvy (SOUND) Cohort

在无既往耐药记录的情况下,从比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺(B/FTC/TAF)稳定转换为多替拉韦/拉米夫定(DTG/3TC):来自比克替拉韦抑制患者转换为多替拉韦(SOUND)队列研究的结果

Slim, Jihad; Bellafiore, Paul; Touza, Masara; Fallon, James P; Borsi, Rebecca A

Prophylactic Beta-Blocker Therapy in Patients Who Underwent Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis

对接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死且左心室射血分数保留的患者进行预防性β受体阻滞剂治疗:系统评价和荟萃分析

Affas, Ziad; Patel, Keyur; Abuzahrieh, Omr R; Al Barznji, Saman; Walji, Mohammed; Touza, Rowaid; Albanna, Manar; Zughaib, Marcel

Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles

利用脂质纳米颗粒对小鼠肝脏进行基因工程改造的PsCas9基因编辑,可实现治疗性基因组编辑。

Degtev, Dmitrii; Bravo, Jack; Emmanouilidi, Aikaterini; Zdravković, Aleksandar; Choong, Oi Kuan; Liz Touza, Julia; Selfjord, Niklas; Weisheit, Isabel; Francescatto, Margherita; Akcakaya, Pinar; Porritt, Michelle; Maresca, Marcello; Taylor, David; Sienski, Grzegorz